BiondVax Pharmaceuticals Ltd. (BVXV)
Chart Events
Performance Outlook
| Previous Close | 1.1800 |
| Open | 1.1900 |
| Bid | 1.1800 x 1300 |
| Ask | 1.2000 x 1300 |
| Day's Range | 1.1900 - 1.1900 |
| 52 Week Range | 1.0000 - 3.4900 |
| Volume | |
| Avg. Volume | 34,141 |
| Market Cap | 22.165M |
| Beta (5Y Monthly) | 2.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.2960 |
| Earnings Date | May 13, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BVXV
Related Research
- BiondVax Pharmaceuticals Ltd.CARA: Lowering target price to $11.00CARA THERAPEUTICS INC has an Investment Rating of SELL; a target price of $11.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.RatingFair ValueEconomic Moat9 months agoArgus Research
- PR Newswire
BiondVax and European Investment Bank sign definitive amendment extending maturity of loan until December 2027 with additional terms in support of BiondVax's new strategy
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative biological medicinal products for the prevention and treatment of infectious diseases and other illnesses, announced today the successful conclusion of negotiations and formal approval by the European Investment Bank (the "EIB") of new terms of its outstanding €24 million loan (the "Loan") to BiondVax.
- Zacks Small Cap Research
BVXV: Significant Progress Made in NanoAb Program…
By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT Business Update Significant Progress Made in NanoAbs Program On May 12, 2022, BiondVax (NASDAQ:BVXV) announced that Dr. Tamar Ben-Yedidia, the company’s Chief Scientific Officer, presented important updates on the NanoAbs program at the Biomed Conference in Tel Aviv, Israel. The company has made a number of recent advancements,
- PR Newswire
BiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-in-human Phase 1/2a safety and efficacy clinical trial
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing a pipeline of innovative NanoAbs for the prevention and treatment of infectious diseases and other illnesses, today announced receipt of supportive minutes of its recent Scientific Advice meeting with the Paul Ehrlich Institute (PEI) in Germany. The Scientific Advice addressed preclinical, clinical, and manufacturing development plans for the COVID-19 NanoAb therapy
